News

FDA Approval

FDA Approves Pembrolizumab Plus Chemoradiotherapy for Patients With Stage III to IVA Cervical Cancer

01/15/2024

Based on results from the KEYNOTE-A18 trial, the FDA has approved pembrolizumab plus chemoradiotherapy for patients with FIGO 2014 Stage III to IVA cervical cancer.

Based on results from the...

01/15/2024

Oncology

News

FDA Approves Enfortumab Vedotin-Ejfv With Pembrolizumab for Patients With Locally Advanced or Metastatic Urothelial Cancer

01/10/2024

Grace Taylor , MS, MA;

The FDA has granted approval to enfortumab vedotin-ejfv with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.

The FDA has granted approval to...

01/10/2024

Journal of Clinical Pathways

News

Addition of Canakinumab to First-Line Pembrolizumab Plus Chemotherapy Did Not Prolong Survival Outcomes Among Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

01/09/2024

Stephanie Holland ;

According to results from the CANOPY-1 trial, the addition of canakinumab to first-line pembrolizumab plus chemotherapy did not prolong PFS or OS among patients with advanced or metastatic non-small cell lung cancer who do not harbor ALK or...

According to results from the...

01/09/2024

Oncology

News

Endoluminal Gemcitabine-Docetaxel as a Renal-Sparing Option for Select Patients With High Grade Upper-Tract Urothelial Carcinoma

01/08/2024

Allison Casey ;

According to a retrospective review, endoluminal gemcitabine-docetaxel demonstrated promising safety and efficacy as a renal-sparing treatment option for patients with high-grade upper-tract urothelial carcinoma.

According to a retrospective...

01/08/2024

Oncology

News

Real-World Data Shows Benefit of Triplet Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer

01/05/2024

Allison Casey ;

A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.

A real world study found triplet...

01/05/2024

Oncology

News

Mirvetuximab Soravtansine Improved Survival, Response Among Patients With Platinum-Resistant, FRα-Positive Ovarian Cancer

12/19/2023

Stephanie Holland ;

According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...

According to results from the...

12/19/2023

Oncology

Conference Coverage

The Potential of Pelabresib Plus Ruxolitinib For Treating Patients With Myelofibrosis: The MANIFEST-2 Study

12/08/2023

Grace Taylor , MS, MA;

A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.

A study by Raajit K. Rampal, MD,...

12/08/2023

Journal of Clinical Pathways

News

Comparing Sacituzumab Govitecan and Physician’s Choice Treatment in HR+/HER2- Metastatic Breast Cancer: TROPiCS-02 Phase 3 Study Analysis

12/06/2023

Grace Taylor , MS, MA;

Aditya Bardia, MD, and colleagues presented their findings from the TROPiCS-02 phase 3 clinical study, which compared the efficacy of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, and treatment of physician’s choice in...

Aditya Bardia, MD, and...

12/06/2023

Journal of Clinical Pathways

News

Disparities in Palliative Care Access Highlighted in Nationwide Study of Deceased Lymphoma Patients

12/04/2023

Brandon Twyford ;

Nationwide study reveals that deceased lymphoma patients receiving palliative care experience significantly lower total charges but no significant impact on adjusted length of stay. The research also highlights disparities in access, with...

Nationwide study reveals that...

12/04/2023

Journal of Clinical Pathways

News

Zanubrutinib Shows Superior Long-Term Outcomes vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

12/04/2023

Emry Lloyd ;

Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.

Jennifer Brown, MD, and...

12/04/2023

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

79458

Recent Stories

Videos

Future Directions in NSCLC Care: Navigating Pathways, Costs, and Cutting-Edge Therapies

11/14/2024

Sawsan Rashdan , MD;

Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.

Dr. Sawsan Rashdan, an associate...

11/14/2024

Journal of Clinical Pathways

News

Enhancing Survival in Endometrial Cancer: Impact of Immunotherapy and Chemotherapy Combination Therapy

11/13/2024

Hannah Musick ;

Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...

Combining immunotherapy with...

11/13/2024

Journal of Clinical Pathways

News

Under 50% of Oncology Practices Offer Survivorship Clinics

11/12/2024

Jolynn Tumolo ;

Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.

Just 41% of oncology practice...

11/12/2024

Journal of Clinical Pathways

Videos

Evolving Oncology Pathways, CLL Treatment Advances, and the Role of Multidisciplinary Care Teams

11/12/2024

Shaffee Bacchus , PharmD;

Shaffee Bacchus, PharmD, discusses the evolution of oncology pathways, advancements in chronic lymphocytic leukemia (CLL) treatment, and the importance of multidisciplinary care teams in addressing comorbidities and enhancing patient quality...

Shaffee Bacchus, PharmD,...

11/12/2024

Journal of Clinical Pathways

Videos

Assessing Fixed-Duration Obinutuzumab, Ibrutinib, and Venetoclax in CLL: A 7-Year Follow-Up

11/08/2024

;

Kerry Rogers, MD, provides a 7-year update on her study that evaluated the progression-free survival and factors associated with undetectable minimal residual disease status after treatment with a fixed-duration combination of obinutuzumab,...

Kerry Rogers, MD, provides a...

11/08/2024

Journal of Clinical Pathways

News

Current Issue

Special Reports

Subscribe

Recent Stories

Specialties

Events

Year Round Education

HMP Global Products